Browse studies
Find your next paid study
75 recruiting studies matching your filters
Phase 2
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Pancreatic Adenocarcinoma
Estimated
~$10 – $6,250
University of LouisvilleNCT03080974
Phase 2
A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic ca…
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Estimated
~$10 – $7,500
Anne NoonanNCT04115163
Phase 1
A Phase Ib Study of 9-ING-41 (Elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy…
Pancreatic Adenocarcinoma
Estimated
~$10 – $7,500
Anwaar SaeedNCT06896188